Our partner is focused on developing genetic medicines for rare and serious diseases, using innovative gene-editing technologies. Their goal is to address unmet medical needs by providing transformative treatments that can improve patient outcomes.

This critical hire led and drove the Drug Substance strategy for peptides and oligonucleotides, ensuring effective communication, connection, and collaboration with CMO partners across global locations.